
Release date: 2026-08-05 16:41:00 Article From: Lucius Laos Recommended: 14
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed countries (extended to July 1, 2033), Laos has been legally permitted to produce generic versions of patented drugs. With significant price advantages, Lao generics have gradually entered the view of domestic cancer and chronic disease patients. Among the many Lao pharmaceutical companies, Lucius Pharmaceuticals is one of the most representative enterprises.
Lucius Pharmaceuticals (Lao) Co., Ltd., founded in 2020 and headquartered in Vientiane, the capital of Laos, has its parent company originating from Hyderabad, India's pharmaceutical hub. The facility covers approximately 210,000 square meters and houses the "Asia Pacific No.1 Smart Factory," with an annual production capacity exceeding 1.5 billion tablets.
In terms of quality certifications, Lucius Pharmaceuticals has obtained GMP certification from the Lao Ministry of Health, ensuring that production environments and processes meet international standards. In October 2023, the World Health Organization (WHO) conducted a comprehensive inspection of the Lucius facility and confirmed that it fully complies with WHO standards.
Regarding products, as of June 2024, Lucius Pharmaceuticals had obtained marketing approvals for 54 anticancer drugs, with total generic varieties exceeding 200, covering oncology, cardiovascular diseases, diabetes, hematology, and other therapeutic areas. Its business has expanded to 12 countries, including Thailand, Indonesia, Vietnam, Japan, and China.
Currently, domestic patients can obtain Lao medicines through the following legal pathways:
Pathway 1: Remote consultation and prescription dispensing via a legitimate Lao internet hospital. Patients submit medical records and diagnostic certificates from formal domestic hospitals, and a licensed physician conducts a remote assessment before issuing an electronic prescription. The medicines are procured directly from GMP-certified manufacturers and shipped internationally under "personal use" rules.
Pathway 2: Online direct shipping from licensed Lao local pharmacies. Licensed Lao pharmacies engage with domestic buyers through online channels, selling medicines directly and shipping them internationally. Legitimate channels typically establish direct sourcing partnerships with leading manufacturers like Lucius, ensuring a complete drug traceability chain.
Operational precautions: The medicines must be strictly limited to personal use by the patient, with each shipment not exceeding a reasonable course duration (generally no more than 3 months). Supporting documents such as ID, medical records, prescription, the manufacturer's Certificate of Analysis (COA), and a copy of the Lao registration approval should be enclosed for customs inspection. According to customs regulations, prescription drugs sent as personal items are subject to reasonable quantities for personal use, with a value limit of RMB 2,000 per shipment.
Risk 1: Mixed channels and widespread counterfeits. Non-official channels lack formal cooperation with manufacturers, cannot provide complete quality documentation, and may even deliver counterfeit products containing no active ingredients.
Risk 2: Illegal sales without a prescription. Lao pharmacy licenses are not valid in China, and there is no domestic internet drug sales qualification. Targeted therapies are prescription drugs, and selling them directly without a prescription poses regulatory violations.
Risk 3: Customs seizure risk. Bulk shipments are more likely to be detained by customs if deemed not for "personal use." Shipping for commercial purposes crosses the red line for drug import regulation.
Risk 4: Transport and storage issues causing drug degradation. Overseas drug shipments may be exposed to high temperatures and humidity during transit, leading to degradation and loss of efficacy.
Identify genuine manufacturer versions from reputable companies like Lucius, and be cautious of unlabeled, suspiciously low-priced medicines. It is advisable to prioritize legitimate internet hospitals officially authorized by the Lao Ministry of Health or compliant agencies with direct sourcing partnerships with manufacturers. Do not blindly pursue low prices; always verify the medicine's source and carry out treatment under the guidance of a qualified physician.
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed countries (extended to July 1, 2033), Laos has been legally permitted to produce ge···【more】
Recommended:15Release date: 2026-08-05
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos have gradually entered the view of Chinese cancer and chronic disease patients due ···【more】
Recommended:26Release date: 2026-08-04
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rapid growth in its generic pharmaceutical industry in recent years. Lucius Pharmac···【more】
Recommended:66Release date: 2026-07-31
Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vientiane, the capital of Laos. The company was established in 2020, with its R&D and operational s···【more】
Recommended:88Release date: 2026-07-28
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Drug CompanyRelocation Background and Strategic ShiftLucius Pharmaceuticals was fo···【more】
Recommended:147Release date: 2026-07-24
In recent years, Laos has gradually become a major global supply source for generic drugs, leveraging the WTO-granted patent exemption for least-developed countries. Among them, Lu···【more】
Recommended:135Release date: 2026-07-22
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was established in 2020, with its headquarters located at No. 26, Thongmang Village···【more】
Recommended:139Release date: 2026-07-20
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operatio···【more】
Recommended:158Release date: 2026-07-17
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos' generic drug industry is rooted in unique international rule dividends. As a U···【more】
Recommended:220Release date: 2026-07-16
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease patients in China due to their significant price advantage. Leveraging the WTO pat···【more】
Recommended:148Release date: 2026-07-15
Regulatory System: From "One Ministry, One Department" to Legal AmendmentsLao drug regulation adopts a centralized "one ministry, one department" management mod···【more】
Recommended:157Release date: 2026-07-14
Overview of Lao generic drug industryThe Lao generic drug industry started late but has developed rapidly in recent years. Relying on the WTO's patent waiver for least develope···【more】
Recommended:166Release date: 2026-07-09
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently made a technical visit to Lucius Pharmaceuticals in Laos. The purpose of the visit was to learn more ab···【more】
Recommended:843Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and mortality, which has been troubling medical workers. Clinical studies have foun···【more】
Recommended:804Release date: 2024-07-09
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 previously untreated CLL/SLL patients aged 65 years and older, ibrutinib demonst···【more】
Recommended:38Release date: 2026-08-03
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the class of ALK inhibitors. Unlike traditional chemotherapy, it does not act by kill···【more】
Recommended:64Release date: 2026-07-30
Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched(1) Quizartinib is an oral tablet. The recommended dose is once daily, one tablet per day (the specific dose is de···【more】
Recommended:78Release date: 2026-07-29
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies for DacomitinibRash and exfoliative skin reactions are highly characteristic adv···【more】
Recommended:122Release date: 2026-07-21
Lao PDR: Filgotinib Has Been LaunchedBefore initiating filgotinib treatment, strict screening for the following contraindications is mandatory; the presence of any one of these con···【more】
Recommended:120Release date: 2026-07-13
Lucius Pharmaceuticals' Pirtobrutinib Has Been LaunchedPirtobrutinib is an oral anticancer drug whose active ingredient is pirtobrutinib, belonging to the class of Bruton's···【more】
Recommended:148Release date: 2026-07-10
Lucius Pharmaceuticals (Lao) Co., Ltd. has launched a generic version of elagolix sodium (trade name LuciElag) for the treatment of moderate to severe pain associated with endometr···【more】
Recommended:156Release date: 2026-07-06
Contraindications for Bempedoic Acid (Nilemdo)Bempedoic acid (Nilemdo) is strictly contraindicated in the following situations: ①hypersensitivity to bempedoic acid or any excipient···【more】
Recommended:155Release date: 2026-07-03
MONDAY, June 15, 2026 — A study published online June 8 in Nature Medicine has found that apitegromab, through its selective inhibition of myostatin, can maintain lean body mass wh···【more】
Recommended:186Release date: 2026-06-24
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combination with BCG (Bacillus Calmette-Guérin) induction and maintenance regimen has rec···【more】
Recommended:290Release date: 2026-06-01
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alf···【more】
Recommended:613Release date: 2025-12-17
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination with abiraterone acetate (brand name: Akeega, Janssen Biotech, Inc.) plus predni···【more】
Recommended:579Release date: 2025-12-15

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643